Literature DB >> 33810845

Atypical periprosthetic femoral fractures of the hip: A PRISMA compliant systematic review.

Annalisa De Cicco1, Giuseppe Toro2, Francesco Oliva3, Umberto Tarantino4, Alfredo Schiavone Panni1, Nicola Maffulli5.   

Abstract

INTRODUCTION: Long-term use of bisphosphonates (BPs) is associated with Atypical Femoral Fracture (AFF). Theoretically, periprosthetic femoral fractures (PFF) should be excluded from the diagnosis of AFF. However, recently several studies reported the occurrence of PPFs around a hip arthroplasty presenting features of an AFF. The present study describes the characteristics of Atypical Periprosthetic Femoral Fracture (APFF) and evaluates the effectiveness of their management through a PRISMA compliant systematic review of the published case reports and series.
MATERIALS AND METHODS: A literature search was performed using "periprosthetic fracture" and "atypical femoral fracture" as keywords. Patients demographics, drug use, clinical and imaging characteristics, stem fixation and classification, management strategies for APFF and patients' outcomes, were also collected.
RESULTS: The present review included and analysed 17 patients from 12 studies. All APFFs occurred in females with a mean age of 75.9 years of age (range 43-87). In 11 patients, APFFs occurred around an uncemented stem, and in 6 around a cemented stem. Ten fractures were incomplete, and 7 complete. Conservative management was effective in 4 of 10 patients with incomplete fracture, while all patients with complete fractures underwent open reduction and internal fixation. A fracture non-union was observed in 5 patients and further surgery was required. DISCUSSIONS: APFFs share several clinical and imaging characteristics with AFF. An appropriate and early diagnosis may allow to improve the outcome of these fractures, the management of which should be based on the same principles of that of AFFs.
CONCLUSIONS: Considering the low quality of published articles and the heterogeneity of the treatment used, a clear recommendation of the most appropriate treatment cannot be formulated.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  Atypical femoral fracture; Bisphosphonates; Osteoporosis; Periprosthetic fracture; Total hip arthroplasty; Treatment

Year:  2021        PMID: 33810845     DOI: 10.1016/j.injury.2021.03.042

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  5 in total

1.  Atypical periprosthetic femoral fracture with stem breakage: a case report.

Authors:  J M Lee; C H Park; J-I Yoo; J-T Kim; Y Cha
Journal:  Osteoporos Int       Date:  2022-06-10       Impact factor: 5.071

Review 2.  Fragility Fractures of the Acetabulum: Current Concepts for Improving Patients' Outcomes.

Authors:  Giuseppe Toro; Adriano Braile; Annalisa De Cicco; Raffaele Pezzella; Francesco Ascione; Antonio Benedetto Cecere; Alfredo Schiavone Panni
Journal:  Indian J Orthop       Date:  2022-05-26       Impact factor: 1.033

3.  Atypical Periprosthetic Femoral Fracture Associated With Prolonged Bisphosphonate Therapy: A Two-Centered Retrospective Case Series and Literature Review.

Authors:  Konlawat Sabsuantang; Thanainit Chotanaphuti; Siwadol Wongsak; Paphon Sa-Ngasoongsong; Saradej Khuangsirikul; Kulapat Chulsomlee; Noratep Kulachote
Journal:  Cureus       Date:  2022-04-26

4.  Surgical and Pharmacological Management of Periprosthetic Atypical Femoral Fractures: A Narrative Literature Review.

Authors:  Elisa Troiano; Tiziano Giacché; Andrea Facchini; Nicholas Crippa Orlandi; Matteo Cacioppo; Marco Saviori; Vanna Bottai; Francesco Muratori; Nicola Mondanelli; Stefano Giannotti
Journal:  Geriatr Orthop Surg Rehabil       Date:  2022-04-11

5.  SuperPath approach is a recommendable option in frail patients with femoral neck fractures: a case-control study.

Authors:  Antonio Benedetto Cecere; Annalisa De Cicco; Gaetano Bruno; Giuseppe Toro; Giacomo Errico; Adriano Braile; Alfredo Schiavone Panni
Journal:  Arch Orthop Trauma Surg       Date:  2021-09-04       Impact factor: 2.928

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.